BioRestorative Therapies Files 8-K: Material Agreement & Equity Sales
Ticker: BRTX · Form: 8-K · Filed: Oct 8, 2025 · CIK: 1505497
Sentiment: neutral
Topics: material-agreement, equity-sale, 8-k
Related Tickers: BRTX
TL;DR
BRTX signed a material deal, sold some stock, and dropped an 8-K. Check it out.
AI Summary
On October 6, 2025, BioRestorative Therapies, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and provided a Regulation FD disclosure. The filing includes financial statements and exhibits.
Why It Matters
This 8-K filing indicates significant corporate activity, including a new material agreement and equity transactions, which could impact the company's financial standing and future operations.
Risk Assessment
Risk Level: medium — The filing details a material definitive agreement and unregistered sales of equity securities, which can introduce financial and operational risks.
Key Players & Entities
- BioRestorative Therapies, Inc. (company) — Registrant
- October 6, 2025 (date) — Date of earliest event reported
- 40 Marcus Drive, Melville, New York 11747 (location) — Principal Executive Offices
FAQ
What is the nature of the material definitive agreement entered into by BioRestorative Therapies, Inc. on October 6, 2025?
The filing indicates the entry into a material definitive agreement, but the specific details of the agreement are not provided in the summary information.
What type of equity securities were sold by BioRestorative Therapies, Inc.?
The filing mentions unregistered sales of equity securities, but the specific type and amount are not detailed in the provided summary.
What is the primary business of BioRestorative Therapies, Inc.?
BioRestorative Therapies, Inc. is in the 'SERVICES-MISC HEALTH & ALLIED SERVICES, NEC' industry, SIC code 8090.
When was BioRestorative Therapies, Inc. incorporated?
The company was incorporated in Nevada.
What is the SEC file number for BioRestorative Therapies, Inc.?
The SEC file number for BioRestorative Therapies, Inc. is 001-37603.
Filing Stats: 1,726 words · 7 min read · ~6 pages · Grade level 13.1 · Accepted 2025-10-08 17:10:43
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value BRTX Nasdaq Capital Mark
- $1.60 — direct offering at an offering price of $1.60 per share (the "Registered Offering").
- $2.75 — arrant Shares") at an exercise price of $2.75 per share. The Registered Offering and
- $1.085 m — gross proceeds of the offering will be $1.085 million, before deducting placement agent
- $8,300 — burse the Placement Agent approximately $8,300 for out-of-pocket expenses for legal fe
- $5.00 — Company's common stock is greater than $5.00 per share for any ten consecutive tradi
- $1.00 — ts for an aggregate redemption price of $1.00 upon at least 30 days prior written not
Filing Documents
- form8-k.htm (8-K) — 57KB
- ex4-1.htm (EX-4.1) — 85KB
- ex5-1.htm (EX-5.1) — 19KB
- ex10-1.htm (EX-10.1) — 51KB
- ex10-2.htm (EX-10.2) — 72KB
- ex99-1.htm (EX-99.1) — 17KB
- ex5-1_001.jpg (GRAPHIC) — 25KB
- ex5-1_002.jpg (GRAPHIC) — 19KB
- ex5-1_003.jpg (GRAPHIC) — 35KB
- ex99-1_001.jpg (GRAPHIC) — 6KB
- 0001493152-25-017446.txt ( ) — 634KB
- brtx-20251006.xsd (EX-101.SCH) — 3KB
- brtx-20251006_lab.xml (EX-101.LAB) — 33KB
- brtx-20251006_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIORESTORATIVE THERAPIES, INC. Dated: October 8, 2025 By: /s/Lance Alstodt Lance Alstodt Chief Executive Officer